Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 10/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | PGR | P06401 | 2/20 | 0.59 |
| ▸ | ESRRG | P62508 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.59 |
| ▸ | PRKCG | P05129 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | PRKCB | P05771 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962745 | 1.00 | ESR1 (0.59) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL3773026 | 0.95 | ESR1 (0.65) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL10506418 | 0.95 | ESR1 (0.65) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL10506428 | 0.95 | ESR1 (0.65) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL30289809 | 0.87 | ESR1 (0.52) | ESR1ESR2MAPTCYP3A4MEN1 | |
| Citric Acid SCHEMBL10954226 | 0.86 | ESR1 (0.68) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL30677997 | 0.86 | ESR1 (0.61) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL10828019 | 0.84 | ESR1 (0.54) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL7547707 | 0.84 | ESR1 (0.60) | ESR1ESR2MAPTCYP3A4MEN1 | |
| SCHEMBL7547715 | 0.84 | ESR1 (0.60) | ESR1ESR2MAPTCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675546-B2 | Method of treating atrophic vaginitis | KLAMERUS BERNADETTE (US) | 2017-06-13 | — | — | US | claimed |
| EP-2205075-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | Tragara Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009042612-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND AROMATASE INHIBITORS OR COMBINATIONS OF COX-2 INHIBITORS AND ESTROGEN RECEPTOR ANTAGONISTS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| US-5945456-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1999-08-31 | — | — | US | claimed |
| US-5847007-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| US-5773479-A | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells | NEORX CORPORATION (US) | 1998-06-30 | — | — | US | claimed |
| EP-0500589-A1 | PURIFIED PROTEIN AND BIOACTIVE PHARMACEUTICAL. | ALFACELL CORP (US) | 1992-09-02 | — | — | EP | claimed |
| WO-1991007435-A1 | PURIFIED PROTEIN AND BIOACTIVE PHARMACEUTICAL | ALFACELL CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| US-4536516-A | Alkene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-08-20 | — | — | US | claimed |
| US-9820990-B2 | Methods of treating disorders associated with protein aggregation | The University of Pittsburgh—Of the Commonwealth System of Higher Education (US) | 2017-11-21 | — | — | US | disclosed |
| US-9693953-B2 | Method of treating atrophic vaginitis | CHOLLET JANET A (US) | 2017-07-04 | — | — | US | disclosed |
| US-9675546-B2 | Method of treating atrophic vaginitis | KLAMERUS BERNADETTE (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160361319-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-12-15 | — | — | US | disclosed |
| US-9480662-B1 | Compositions and methods for topical tamoxifen citrate therapy | CHOLLET JANET A (US) | 2016-11-01 | — | — | US | disclosed |
| WO-1995010513-A1 | BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS | PFIZER INC. (US) | 1995-04-20 | — | — | WO | disclosed |
| EP-0287690-B1 | STABLE SOLVENT ADDUCTS OF Z-1-(P-BETA-DIMETHYLAMINO-ETHOXYPHENYL)-1-(P-HYDROXYPHENYL)-2-PHENYLBUT-1-ENE | HEUMANN PHARMA GMBH & CO (DE) | 1992-09-02 | — | — | EP | disclosed |
| US-4973755-A | ANTIESTROGENS | HEUMANN PHARMA GMBH & CO. (DE) | 1990-11-27 | — | — | US | disclosed |
| US-4656187-A | SYNERGISTIC COMBINATION | ELI LILLY AND COMPANY (US) | 1987-04-07 | — | — | US | disclosed |
| US-4536516-A | Alkene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-08-20 | — | — | US | disclosed |
| US-4418068-A | Antiestrogenic and antiandrugenic benzothiophenes | ELI LILLY AND COMPANY (US) | 1983-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361319-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION | HTT, ATIC, API5 | ESR1 1148/4885ESR2 1874/4885MAPT 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.